key: cord-0789377-9gv4unjw
authors: Wang, Xiaofeng; Jehi, Lara; Ji, Xinge; Mazzone, Peter J.
title: Phenotypes and Subphenotypes of Patients with COVID-19: a Latent Class Modeling Analysis
date: 2021-02-26
journal: Chest
DOI: 10.1016/j.chest.2021.01.057
sha: 9c643a80189577bda850b144d609bd1b1432a809
doc_id: 789377
cord_uid: 9gv4unjw

Background Since COVID-19 was identified, its clinical and biological heterogeneity has been recognized. Identifying COVID-19 phenotypes might help guide basic, clinical, and translational research efforts. Research Question Does the clinical spectrum of patients with COVID-19 contain distinct phenotypes and subphenotypes? Study Design and Methods: We included adult patients (≥18 years old) who were laboratory-confirmed SARS-CoV-2 positive from a prospective COVID-19 registry database in the Cleveland Clinic Health System in Ohio and Florida. The patients were split into training and testing sets. Using latent class analysis (LCA), we first identified phenotype clusters of patients with COVID-19 based on demographics, comorbidities, and presenting symptoms. We then identified subphenotypes of hospitalized patients with additional blood biomarker data measured at hospital admission. The association of phenotypes/subphenotypes and clinical outcomes were investigated. Multivariable prediction models were established to predict assignment to the LCA-defined phenotypes and subphenotypes and then evaluated on an independent testing set. Results We analyzed data for 20,572 patients. Seven phenotypes were identified based on different profiles of presenting COVID-19 symptoms and existing comorbidities, including Young-no-symptom; Young-symptom; Middle-aged-no-symptom; Middle-aged-symptom; Middle-aged-comorbidities; Old-no-symptom; and Old-with-symptom groups. The rates of inpatient hospitalization for the phenotypes were significantly different (p<0.001). Five subphenotypes were identified for the subgroup of hospitalized patients, including Young, elevated WBC and platelet counts; Middle-aged, lymphopenic with elevated CRP; Middle-aged, hyperinflammatory; Old, leukopenic with comorbidities; Old, hyperinflammatory with kidney dysfunction subgroups. The hospital mortality and the times from hospitalization to intensive care unit transfer or death were significantly different (p<0.001). The models for predicting the LCA-defined phenotypes and subphenotypes showed high discrimination (C-index, 0.92 and 0.91). Interpretation Hypothesis-free LCA-defined phenotypes and subphenotypes of COVID-19 patients can be identified. These may help clinical investigators conduct stratified analysis in clinical trials and assist basic science researchers in characterizing the pathobiology of the spectrum of COVID-19 presentations.

The clinical spectrum of COVID-19 is broad, ranging from asymptomatic infection to severe pneumonia with respiratory failure. Many studies have reported on the clinical characteristics of COVID-19 [1] [2] [3] [4] [5] . The largest cohort study reported to date included 72,314 cases from the Chinese center for disease control and prevention 6 . In this study, 81% of patients had mild to moderate disease (mild symptoms up to mild pneumonia), 14% had severe disease (dyspnea, hypoxia, or >50% lung involvement on imaging), while 5% had critical disease (respiratory failure, shock, or multiorgan system dysfunction). These findings drew early broad brushstrokes of the clinical disease spectrum. A more complex picture later emerged, with symptoms extending beyond the respiratory system, and unpredictable clinical deterioration in patients initially thought to have mild disease. This uncovered a need for a more sophisticated classification mirroring the heterogeneous clinical progression. In parallel, several efforts have evaluated laboratory-based disease biomarkers. Guan et al. 5 found that elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, lactate dehydrogenase, creactive protein (CRP), and ferritin levels may be associated with greater illness severity manifest by acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI), resulting in a higher mortality rate.

The clinical and biological heterogeneity of COVID-19 7,8 has led to an incomplete categorization of disease phenotypes. In contrast, research in cancer, ARDS, and asthma has been able to identify disease phenotypes with important therapeutic implications [9] [10] [11] . Currently, a Latent Class Analysis (LCA), a subset of structural equation modeling, is a well-validated statistical technique for identifying unmeasured class membership among subjects using categorical and/or continuous observed variables 12 . It uses mixture modeling to find the bestfitting model under the assumption that individuals can be divided into subgroups based on an unobservable construct. The subgroups are called latent classes. LCA is an unsupervised analysis in that it asks whether there are subgroups of individuals defined by a combination of variables, without mandating consideration of an outcome. LCA has been successfully used in respiratory and critical care medicine, for example, in the identification of phenotypes of childhood asthma 9 and subphenotypes of ARDS 11 . Despite widespread recognition of the heterogeneity within COVID-19, little work has robustly studied if/what subphenotypes exist. This paper aims to take advantage of the wealth of clinical and blood biomarker data available from the prospective COVID-19 Registry of the Cleveland Clinic Health System 13 by using latent class modeling approaches to identify phenotypes and subphenotypes of COVID-19 patients and to test their association with clinical outcomes. COVID-19 was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) for SARS-CoV2. The testing protocols were previously described 13 .

Patients' demographics, comorbidities, presenting symptoms, and medications were retrieved and analyzed. Comorbidities including cancer, COPD/emphysema, asthma, diabetes mellitus, hypertension, coronary artery disease, transplantation, multiple sclerosis, inflammatory bowel disease, and immunosuppressive disease were extracted from the electronic health record (Epic; Epic Systems Corporation, Madison, WI). The immunosuppressive disease was defined based on the Agency for Healthcare Research and Quality's (AHRQ) patient safety indicator (PSI) Appendix I -Immunocompromised State Diagnosis Codes.

For hospitalized patients, routine blood examination results from hospital admission were extracted, including complete blood count, basic metabolic panel, coagulation profile, renal, and liver function tests. We excluded the blood biomarkers if they were missing for ≥ 30% of subjects. We finally selected 17 candidate blood biomarkers based on the current literature 1-6 .

They represented a diverse range of biological processes, including absolute lymphocyte count, absolute neutrophil count, albumin, alanine aminotransferase (ALT), alkaline phosphatase (ALP), BUN, chloride, c-reactive protein (CRP), creatinine, ferritin, hematocrit, hemoglobin, J o u r n a l P r e -p r o o f 8 platelets, potassium, red-blood-cell distribution width (RDW), total bilirubin, and white blood cell (WBC) count.

For all patients who tested positive for SARS-CoV-2, the primary outcome measured was the need for inpatient hospitalization. For the subgroup cohort of hospitalized patients, the primary outcome measured was a composite of transfer to an intensive care unit (ICU) or inhospital mortality (WHO COVID-19 Outcomes Scales 6-8) vs. no transfer to ICU and alive (Scales 3-5) during hospitalization. The secondary outcome for hospitalized patients was inhospital mortality only. Patients still hospitalized at the time of analysis were censored. The outcomes for all patients were followed up until December 5, 2020.

The study patients were split into training and testing sets based on the time they entered the database. The patients collected before August 28, 2020, were considered as the training sample, while the patients collected between August 29 to October 31, 2020, were used as the testing sample. The study variables were described using sample median with inter-quartile range (IQR) or number with proportion. Categorical variables were compared using Pearson's chisquare test or Fisher's exact test, whereas continuous variables were compared using Mann-Whitney U test. We developed two latent class models in this study: the first one was for all patients who tested positive; the second one was for hospitalized patients only.

The candidate class-defining variables in the first model included demographics, comorbidities, and presenting symptoms. BMI was excluded as it was missing in 47% of the Kruskall-Wallis, Pearson chi-square, and Fisher's exact tests, as appropriate, were performed to compare the clinical, laboratory, and outcome variables between the resulting classes. Kaplan-Meier survival analysis was conducted to describe survival characteristics among the different sub-classes in hospitalized patients. Finally, we built multinomial logistic regression models with the bias correction method 18, 19 to predict latent class membership.

Bootstrap internal validation was conducted to assess the models' discriminative ability.

All analyses were performed by using the R software program (version 3.6.3; R Foundation for Statistical Computing, Vienna, Austria) and SAS software (version 9.4; The SAS Institute, Cary, NC). The level of statistical significance was set at p < 0.05 (two-tailed).

There were 285,783 patients who presented with symptoms of respiratory tract infection or had close contact with someone with confirmed COVID-19 from March 12 to October 31, 2020, and who underwent SARS-CoV-2 testing. Of the 21,978 patients who tested positive for SARS-CoV-2, 20,572 adult patients served as the study population ( Figure 1 ). The patients were split into the training and testing sets, where 11,818 patients were included in the model training and 8,754 patients served as the testing cohort. A total of 3,546 patients (2,655 and 891 patients in the training and testing sets, respectively) were admitted to a hospital in the Cleveland Clinic

Health System, which served as the sub-population in the subgroup analysis. Baseline demographic and clinical characteristics of the training and testing cohorts in the study are presented in Tables S1 to S4 in the supplement.

The best-fitting model, as indicated by the BIC, was a seven-class model using 1 demographic variable, 6 symptom variables, and 7 comorbidity variables: the demographic variable was age; the symptom variables included the presences of cough, fever, fatigue, sputum production, shortness of breath, and diarrhea; the comorbidity variables included the presence of asthma, COPD/emphysema, diabetes, hypertension, coronary artery disease, heart failure, cancer, and immunosuppressive disease. Table 1 displays the group comparison results to help us understand the clinical characteristics that distinguished each phenotype.

Phenotype Class 1 (Young, no symptom; 32% of the sample) and Phenotype Class 2 (Young, symptom; 14% of the sample) contained mostly young adults, with median ages 33 and 34 years, respectively. Patients in Class 1 had very few COVID-19 symptoms and comorbidities.

Patients in Class 2 also had few comorbidities but did have typical COVID-19 symptoms, such as cough (85%) and fever (65%).

Phenotype Class 3 (Middle-aged, symptom; 8% of the sample), Phenotype Class 4 (Middle-aged, no symptom; 21% of the sample), and Phenotype Class 5 (Middle-aged, comorbidities; 11% of the sample) was more heavily populated with individuals with median ages 56, 61, and 59 years, respectively. Patients in Class 3 had almost all common COVID-19 symptoms, while patients in Class 4 had nearly no COVID-19 symptoms. In contrast, some symptoms were common (cough, 82%; fever, 61%; fatigue 50%) but some were not (sputum production, 27%; shortness of breath, 38%; diarrhea, 20%, vomiting, 13%) in Class 5.

Comorbidities were more common in the three middle-aged groups than the young adult classes.

The frequencies of hypertension, diabetes, and cancer in Class 4 and Class 5 were much higher than in Class 3.

Phenotype Class 6 (Old, no symptom; 8% of the sample) and Phenotype Class 7 (Old, symptom; 6% of the sample) were populated with median ages 74 and 76 years. Patients in Class 6 had few COVID-19 symptoms, while those in Class 7 had almost all common symptoms. Both classes had high frequencies of comorbidities.

[Insert Table 1 here] The Chi-square analysis showed a significant association between the LCA-defined phenotypes and inpatient hospitalization (p<0.001). The rates of inpatient hospitalization for the seven phenotypes were 9.7%, 9.8%, 22%, 24%, 33%, 47%, and 59%, respectively.

The best-fitting model, as indicated by the BIC, was a five-class model using 4 clinical variables and 7 blood biomarkers. The clinical variables included age, the presence of cancer, the presence of COPD/emphysema, and the number of other comorbidities, and the blood biomarkers included: WBC count, lymphocyte count, CRP, creatinine, albumin, platelet count, and hemoglobin. Table 3 displays the class comparisons' results to illustrate the clinical and biological characteristics that distinguished each subphenotype. Figure 2 shows the latent profile plots of the subphenotypes identified.

[Insert Table 2 We performed Kaplan-Meier survival analysis for the two time-to-event outcomes by subphenotypes: time to ICU transfer or in-hospital mortality and time to in-hospital mortality. As shown in Figure 3a , patients in Subclasses 3 and 5 had much higher probabilities of being transferred to ICU or in-hospital mortality than patients in Subclasses 1 and 2. When we investigated the time-to-in-hospital-mortality only, Figure 3b shows that Subclasses 4 and 5 had worse overall survival than the other three classes. Patients in Subclass 3, although having a high chance of being transferred to the ICU, appeared to have a more favorable survival than Subclass 4. The p-values of the log-rank tests for the two outcomes were <0.001 when comparing the five subphenotypes.

[Insert Figure 3 here]

We established two multivariable prediction models to predict assignment to the LCAdefined phenotypes and subphenotypes, respectively. For phenotypes of patients with COVID-19, we used one demographic variable, age, three symptom variables, cough, fever, and diarrhea, and three comorbidity variables, cancer, diabetes, hypertension, in the model. With the seven variables, the concordance index (c-index) for the phenotype prediction using bootstrapped internal validation was 0.92.

For subphenotypes of hospitalized patients, we used four of the blood biomarkers with the greatest difference in mean absolute values between phenotypes as predictive markers, and two clinical variables in a predictive modeling analysis. With six variables (creatinine, albumin, CRP, WBC, age, cancer/COPD/emphysema[yes or no]), the c-index was 0.91. The estimated parameters of the two prediction models for assignment to the LCA-defined phenotypes and subphenotypes are presented in Tables S2 and S3 in the supplement. We developed an online calculator to predict the LCA-defined phenotypes and subphenotypes ( Figure S1 ), available at: https://riskcalc.org/COVID19phenotypes/.

We validated the accuracy of outcome prediction using the phenotype and subphenotype groupings on an independent test set and compared the accuracy to models based on age and the presence of key comorbidities alone. In Table 3 , we summarize the c-indices of fifteen different models applied to the independent testing cohort. The c-indices for the models using the phenotype or subphenotype stratification were uniformly better than the models using age and/or the presence of key comorbidities.

[Insert Table 3 here]

This study is the first study to include a large COVID-19 patient cohort with comprehensive demographic, clinical, and blood biomarker data, exclusively focused on objective disease sub-classification into clinical phenotypes. We applied latent class modeling, a modern statistical technique that allows us to capture the clinical and biological heterogeneity of COVID-19 patients. Our findings provide proof-of-concept that the clinical spectrum of COVID-19 contains distinct subphenotypes based on patients' clinical information and blood biomarkers available at hospital admission.

Prior publications have identified isolated predictors of severe disease progression, but such information has limited potential to impact clinical decision-making significantly. In fact, no single clinical variable or biomarker was sufficient to identify the subphenotypes in our study, which translates into the reality of clinical practice whereby patients do not usually fall into clean buckets of "all good" or "all bad" outcome predictors, and where clinical outcomes are rarely-if ever-driven by one patient characteristic. However, when considered together, the variables J o u r n a l P r e -p r o o f identified in our study form plausible and coherent clusters of COVID-19 patients, and our LCAdefined phenotypes and subphenotypes may indicate different disease mechanisms.

Our findings provide an objective phenotypic classification reflecting the emerging literature on critical drivers of disease pathophysiology in COVID-19. In summary, of the phenotypes of patients who tested positive, classes 1 and 2 were young people with or without symptoms: about 10% were hospitalized. Classes 3, 4, and 5 were middle-aged people with or without symptoms and different comorbidity patterns: 22~33% were hospitalized. Classes 6 and 7 were old adults: if they had no or few symptoms, the hospitalization rate was close to 50%. If they had a lot of symptoms, the rate was close to 60%. Table 3 demonstrates that our LCA phenotypic model is a better predictor of hospitalization and J o u r n a l P r e -p r o o f of progression to ICU admission or mortality than a risk assessment based on age and comorbidities alone. This supports an incremental benefit to our model over existing knowledge.

In addition, our findings in Figures 3a and 3b suggest potentially relevant clinical implications. For example, Subclass 2 has the second-highest survival probability in 3a but tied for the lowest in 3b, raising the hypothesis that late transfer to the ICU may have influenced/delayed the death outcome in this class. It is possible that late complications (thromboembolic events or secondary infections) were potentially avoided by higher care intensity in the ICU. Similar questions could apply to Subclass 4. Conversely, Subclass 5 was quickest to get to the ICU or die in 3a and had the highest death rate in 3b. Is ICU transfer or transfer time futile for this group? Subclass 3 also had a fast transfer time but substantially lower rate of death than Subclasses, 5, 4 and 2. Should this be a group we focus our resources on?

These are all speculations at this point, but warrant further investigations with future studies.

Our study has some limitations. First, we did not include radiological features in the LCA. Robba et al. 24 described three distinct radiological phenotypes of severe COVID-19 pneumonia and suggested that their radiological phenotypes could redefine clinical management.

Radiological features of COVID-19 may add to the power to improve classification performance mortality, which might be associated with the prognosis of COVID-19. We were unable to consider them in our analysis because BMI was missing in 47% of the cohort. These variables could contribute to phenotype identification but were not available for this analysis. Finally, we considered that our COVID-19 data registry is a valid source of data for the assessment of comorbidities at a population-based level. Given the chronic aspect of comorbidities, we assumed that the patient suffers from that comorbidity up until the time of COVID-19 diagnosis once a comorbidity is recorded in our electronic health record. However, the evaluation of comorbidities depends heavily on both age and the probability of attending the hospital (inpatient or outpatient) in the years preceding the COVID-19 diagnosis. We did not systematically evaluate the accuracy of data about comorbidities and smoking history, and did not have data about the severity of the comorbid conditions. A limitation of the outcome used to assess the first latent class model is that the decision about who to hospitalize is not standardized. We also lacked the laboratory test results over time, which limited us to study the disease progression. Table 3 : The comparison of prediction performance by using phenotype or subphenotype vs. age and/or the presence of cancer/COPD/emphysema in prediction models: Fifteen different models applied on the testing cohort in predicting different outcomes. "Age group" denotes the categorical variable that patient's age was categorized by decade; "Age" denotes the continuous variable of patient's age. "ALT" is in a logarithmic scale in the model. 

Baseline Characteristics and Outcomes of 1591

Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of coronavirus disease 2019 in China

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

Clinical and epidemiologic phenotypes of childhood asthma

Phenotypic Heterogeneity of Potentially Curable Non-Small-Cell Lung Cancer: Cohort Study with Cluster Analysis

Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials

Applied latent class analysis

Individualizing risk prediction for positive COVID-19 testing: results from 11,672 patients

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19)

Variable selection for latent class analysis with application to low back pain diagnosis

depmixS4: an R package for hidden Markov models

Estimating latent structure models with categorical variables: One-step versus three-step estimators

Latent class modeling with covariates: Two improved three-step approaches

Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan

Analysis of inflammatory parameters and disease severity for 88 hospitalized COVID-19 patients in Wuhan

Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China

Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry

Distinct phenotypes require distinct respiratory management strategies in severe COVID-19

Multi-Center Study of Temporal Changes and Prognostic Value of a CT Visual Severity Score in Hospitalized Patients with COVID-19